OXiGENE (NASDAQ:OXGN)‘s stock had its “buy” rating reissued by Zacks in a research note issued to investors on Friday May 1st.
Separately, analysts at MLV & Co. set a $6.50 price target on shares of OXiGENE and gave the company a “buy” rating in a research note on Wednesday, March 18th.